However, nutritional support only, as any other monotherapy, will probably not be sufficient.44 Therefore, future research should focus on nutritional support and other pharmacological agents to counterbalance the detrimental effects of skeletal muscle depletion in patients with necrotizing pancreatitis.44 Alternative treatment options, such as myostatin inhibition, which reduces skeletal muscle wasting,45 are currently being investigated in phase II clinical trials in cancer patients46 and might prove useful in acute pancreatitis. This evidence concerns the gene MSTN and cancer.